Market Place
Sourcing Support
All News #Library
Rare Diseases
Biogen Bets on $5.6 Billion buyout of Apellis
31 Mar 2026 //
GLOBENEWSWIRE
NEJM Publishes VALIANT EMPAVELI Results for C3G & Primary IC-MPGN
03 Dec 2025 //
GLOBENEWSWIRE
Apellis snatches broad kidney Disease Expansion for Empaveli
29 Jul 2025 //
FIERCE PHARMA
Apellis Expands Empaveli Use for Broad Kidney Disease
28 Jul 2025 //
FIERCE PHARMA
Apellis to Get $300M from Royalty Deal with Sobi for Aspaveli
01 Jul 2025 //
GLOBENEWSWIRE
Sobi Modifies Apellis Agreement for Aspaveli`s Ex-U.S. Royalties
01 Jul 2025 //
PR NEWSWIRE
Apellis, Sobi Report Ph3 Data For EMPAVELI In C3G, IC-MPGN
06 Jun 2025 //
GLOBENEWSWIRE
Novartis, Apellis roll out rival datasets in rare kidney disease
28 Oct 2024 //
FIERCE PHARMA
Apellis Pharma draws takeover interest
03 Apr 2023 //
FIERCE PHARMA
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.